


Bioengineering: An Interface with Biology and Medicine
Prof. Sanjeeva Srivastava
Department of Biosciences and Bioengineering
Indian Institute of Technology - Bombay

Lecture – 20
Clinician's Perspective-III

Welcome to MOOC-NPTEL course on bioengineering, an interface with biology and medicine. In order to bridge the gap between engineers and doctors, we have invited couple of clinician's in this course to bridge that gap and get the clinician's perspective on the biology for engineers. Today I have with me a very distinguished colleague and scientist, Dr. Jayanthi Shastri with us.
(Refer Slide Time: 00:45)



Dr. Shastri is currently a professor and head of the microbiology department at TNMC and BYL Nair Hospital in Mumbai. On completion of MD in clinical microbiology, Dr. Shastri pursued her interest in infectious disease diagnosis with special reference to validating new and rapid diagnostic techniques for dengue, malaria and HIV.

(Refer Slide Time: 01:02)

Interests in Infectious disease diagnosis

- Validating new and rapid diagnostic techniques for Dengue, Malaria and HIV.



TNMC and BYL Nair Ch. Hospital


(Refer Slide Time: 01:11)



State-of-the-art molecular diagnostic laboratory, Mumbai

Dr. Shastri planned and commissioned a state of the art molecular diagnostic facility at the infectious disease hospital in Mumbai.

(Refer Slide Time: 01:21)



Her laboratory is recognized by the national AIDS control organization as regional HIV reference laboratory for conducting HIV viral loads by real time PCR and early infant diagnosis by DNA PCR.

(Refer Slide Time: 01:37)



She is the chairperson for Animal Ethics Committee and Vice president research society of TN medical college and Nair hospital. She has authored several articles in national and (()) (01:50) journals. Dr. Shastri has obtained several awards.

(Refer Slide Time: 01:56)



Dr. Jayanthi Shastri

- “ Visiting scientist ” at Albert Einstein College of Medicine (AECOM)
- Recipient of CFAR grant from AECOM
- “ Teaching Professorship ” award from American society of Microbiology

She was funded as visiting scientist at Albert Einstein College of Medicine in New York in 2009 under AIDS international training program. She was also a recipient of CFAR grant from AECOM to conduct a pilot study of HIV among women attending a health clinic in Mumbai. In October 2015, she has received teaching professorship award from American society of Microbiology to teach infectious disease at University of South Florida.

I must say that, you know, we have had very nice systematic interaction with Dr. Jayanthi Shastri over the period of time when we were working with her on different infectious disease problems and her clinical perspective has been a very motivating for the students to really take these kind of challenges forward. I am sure she is going to enlighten and give her perspective on how infectious diseases are still so challenging.

And there is so much room, so much need to have intervention for engineering technologies in this area. So let me welcome Dr. Jayanthi Shastri for her lecture.

(Refer Slide Time: 03:05)



(Video Starts 03:10 - Video Ends 22:48)

(Refer Slide Time: 03:10)



So very good afternoon to all of you. It is actually my very very proud privilege to be talking to such bright students of the Indian Institute of Technology. I cannot thank Dr. Sanjeeva enough for giving me this opportunity. So what I really wanted to talk to you is about the challenges and opportunities we have in infectious disease diagnosis and just to walk you through what we currently do in terms of infectious disease diagnosis and what is a possibility.


(Refer Slide Time: 03:49)



So this is the lab I head. We do molecular diagnosis for commonly the acute febrile illnesses which is dengue, malaria, typhoid, hepatitis and we also are the regional HIV reference lab. So we do what is called as early infant diagnosis for testing HIV in the newborn babies at 6 weeks and also do the HIV viral loads. So we are part of the national program.

So anybody who is interested in seeing molecular diagnostics by real time PCRs for these infectious diseases, you are welcome. So as we can see microbes, so when we say infectious agents of disease. There are number of infectious agents of disease. An infectious disease as we all know is the scourge of mankind.

(Refer Slide Time: 04:47)



There have been older diseases like plague, like whooping cough, like diphtheria and we have been able to completely eliminate these diseases by vaccination. And what is now we are faced with are emerging infectious diseases and that would be the last lag of my talk. So when we talk of bacteria, they could be both gram positive and gram negative. Why is it important? Because the antibiotics which we use for gram positive organisms are different from those which we use for gram negatives.

That is because of their inherent cell wall nature. The gram positive organisms have more of peptidoglycan and the gram negatives have got more of lipids. And we can see that bacteria, viruses. The dengue is a virus; hepatitis is the virus. Then parasites, we have malarial parasite, trypanosomiasis and we have all the worm infestations. These are all parasites. Fungi could be Candida, Cryptococcus, histoplasmosis.

Other fungi which infect human beings. When it comes to a clinical sample which we receive in the laboratory for testing, for the infectious disease agents, we get all these kind of samples, the blood samples, stool samples, urine, nasopharyngeal aspirates, pus aspirates. We do not know whether this clinical sample has got bacteria, viruses, fungus, or a parasite. So we have to put it through a battery of tests in order to individually identify these pathogens. The other alternative is do molecular diseases by multiplex PCR.

(Refer Slide Time: 06:38)



And what is multiplex PCR? We have targets for bacteria, viruses, parasites, all put together, the (()) (06:47) instant of 20 pathogens in the respiratory sample and we look for the presence of any of these agents. Why is it important for us to know? Because with bacteria, what we can do is the antimicrobial susceptibility testing which is done by the conventional method in the laboratory using Muller-Hinton agar and we streak the plate with the microorganism, look for the zones of inhibition. But what we have seen is drug-resistance is on the rise.

(Refer Slide Time: 07:26)




So we need to know whether the clinical sample has got drug-resistant bugs or it has drug-sensitive bugs. Whether artemisinin which is given as a drug of choice for malaria is the parasite resistant or is it sensitive to that drug. So these are certain questions which always bog our minds when we are treating patients and when we are giving her diagnosis.

(Refer Slide Time: 07:52)

Combatting antibiotic Resistance

How does antibiotic resistance occur?




And how do, how does antibiotic-resistance come up? So there is a mixture of drug-sensitive and drug-resistant organisms and one organism to the other elements which are responsible for drug-resistance are transferred from one bacteria to other.

(Refer Slide Time: 08:11)

CHALLENGE & OPPORTUNITY


- Is the Infection due to Bacteria, Virus, Fungus or a parasite ? (Due to differences in cell wall constituents)
- Is the Infecting agent sensitive or resistant to simple antibiotics or needs higher antibiotics ?



So what is our challenge? Is the infection due to bacteria? due to virus, due to fungus, or a parasite. These are due to differences in the cell wall. It is able, you can use simple methods for identification because of cell wall differences. Whether the infecting agent is sensitive or resistance to simple antibiotics or you need higher antibiotics. Now I have just shown you our known methods that is through a DNA sequencing and this is a genomic analyzer.

This is just a microchip with microfluidics. These are certain methods which can be employed to answer these questions. However, these are very time consuming and the clinician really has to wait a couple of days before he gets the answers. So what is the need of the hour? I need a point of care test, a lab on chip.

(Refer Slide Time: 09:17)




I need a chip which can tell me whether it is a bacteria or virus. Another thing that would be my next path which is how is it beneficial to the clinician? To know whether it is a bacteria, whether it is a virus or a fungus or a parasite, okay. So this is the food for thought for all you bright students, we need a very sensitive another specific test which is available at the bedside.

(Refer Slide Time: 09:40)




The sample also need not go to the laboratory. At the bedside, you can do this test. Whenever I get a viral pharyngitis, a sore throat and we will take antibiotics. Why? Because of selection pressure of the antibiotics. The next time I get infected, I may be resistant to the antibiotics which I have taken. So that is called abuse of antibiotics. So we have to use antibiotics very rationally and not use it for viral and parasitic infections and limit its use only for bacterial infections.

(Refer Slide Time: 10:17)



Advantages to the Clinician

- Rational Use of Antibiotics & No antibiotics given for Viral & Parasitic Infections.
- Antibiotic stewardship
- Turn around time (TAT) to diagnose infectious diseases is markedly reduced.
- Providing Evidence based Diagnosis

 Email : jshetri@gmail.com 18

So we create a good antibiotics stewardship by antibiotic cycling. Now with these good point of care tests, the turnaround time for diagnosis of infectious diseases would also be reduced and it will give evidence day we are in the era of evidence based medicine. We do not grope in the dark to see what the infection probably could be. There is nothing called as probability. There has to be an evidence.

(Refer Slide Time: 10:46)



Now coming to the monsoon period, we all experienced this terrible Tuesday in 2005 when the Mumbaikers were all, you know, soaked.

(Refer Slide Time: 11:00)



And this was the scene and what do we see during these times?

(Refer Slide Time: 11:06)

Important Diseases

- Leptospirosis
- Dengue
- Malaria
- Typhoid
- Cholera
- Hepatitis



Email : jshastri@gmail.com

21

These are the diseases which we have to face.

(Refer Slide Time: 11:09)

DIAGNOSTIC DILEMMAS



Perseverance is a great element of success. If only you knock enough and loud enough at the gate, you are sure to wake somebody up.

H.W. Longfellow



22

And there are diagnostic dilemmas as to what this infection probably could be. Patient presents with fever, headache, malaise, joint pains, rash. What is it? Is it dengue, is it malaria, is it leptospirosis? So we are still grappling with this problem and what do we do? Then in dengue we have also seen that some patients present with severe dengue and some people present with less severe, self-limiting dengue fever.

(Refer Slide Time: 11:35)

DENGUE : Clinical MF



- All four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS)
- The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved as there are no human models




Email : jashatri@gmail.com

23

Others have dengue shock syndrome, dengue hemorrhagic fever.

(Refer Slide Time: 11:42)





And what are the detection methods? At my end in the laboratory as I told you, we individually test for malaria, for Leptospira and for dengue. We have the antigen testing methods by serology. We have PCRs which we do. We look for the viral RNA, dengue specific RNA by real-time chemistries, the Taqman chemistries.

(Refer Slide Time: 12:07)

Malaria

- Severe malaria is most commonly caused by infection with *Plasmodium falciparum*, although *P. vivax* and *P. knowlesi* can also cause severe disease.
- The risk is increased if treatment of an uncomplicated attack of malaria caused by these parasites is delayed.
- **Recognizing and promptly treating uncomplicated malaria is therefore of vital importance.**
- Sometimes, however, especially in children, severe *P. falciparum* malaria may develop so rapidly that early treatment of uncomplicated malaria is not feasible.





Email : jshastri@gmail.com

25


And we have serology, that is look for the antibodies which are both IgM and IgG. IgG is for secondary dengue and malaria.


(Refer Slide Time: 12:20)

CHALLENGES & Opportunity

- Which individual will progress to Severe Disease in Dengue & Malaria ?

GENETIC PREDISPOSITION OR HOST RESPONSE ?






Email : jshastri@gmail.com

26

Severe malaria is most commonly caused by infection due to *Plasmodium falciparum*, *vivax*, (()) (12:25). The risk is increased if treatment of an uncomplicated attack of malaria caused by these parasites is delayed and recognizing uncomplicated malaria is of vital importance and in children, *Plasmodium falciparum* malaria may develop so rapidly that early treatment of uncomplicated malaria is not feasible. So what is the challenge? Is diagnosing these infections well in time?

(Refer Slide Time: 12:58)

BIOMARKERS IN DISEASE PROGRESSION



Email : jshastri@gmail.com

27


And also knowing which of these patients are going to progress to severe malaria or severe dengue. We have a collaborative project with Dr. Sanjeeva, the PhD student Apoorva is working on severe vivax malaria and looking for a protein markers in severe malaria. So this is underway and it is showing a lot of promise in understanding the pathogenesis of malaria. Now having said that, everything has to transmit into better diagnostics.

As a clinician, as an infectious diseases diagnostics person, I need a test which will be full proof, which will be available at the bedside, which would not be very expensive. So this is wishful thinking, right. But I am sure all of you have understood the magnitude of this problem and I really going to put your heads together in helping us get better diagnostics so that for the betterment of patient care.

So we all the, mix the transcriptomics, proteomics, genomics, metabolomics, all this addressing these issues of better diagnostics. But we need a point of care test.

(Refer Slide Time: 14:26)

BIOMARKERS IN DISEASE PROGRESSION



So and the other thing is biomarker. A potential biomarker which will tell me which of these infections is going to progress. So this is going to help the clinician with diagnosis, prognosis and treatment. So the new way either I have the mass spectroscopy is again going to take time. So I need something like a point of care test.

Genomics is going to take time. In fact, we in molecular diagnosis, give the report by the end of the day when we get the samples in the morning by 9:00 a.m., but we want something much more quicker and much more faster.

(Refer Slide Time: 15:02)

Nanotechnology in Diagnosis

- Development of diagnostics that can quickly identify the infectious agent
- Conventional techniques are limited by speed of analysis, need for skilled workers, poor detection threshold and inability to detect multiple strains of infectious agents.

The diagram shows a microarray chip with various components labeled: Sample, Probe, Label, Readout, 25 mm, and 14 mm.


NPTEL
Email : jshastri@gmail.com 20

So nanotechnology also holds a lot of promise in diagnosis of infectious diseases. It can quickly

identify the infectious agent so that we come to know which is a severe case, we can quarantine a patient. Quarantine of patients is important in order to prevent patient to patient spread. So the conventional techniques are not very fast. We need skilled workers, poor detection threshold like we have the HIV viral load testing which requires at least 50 copies of the HIV virus to be present for the test to be positive.

So can we have a test which can detect lower copies of the virus?

(Refer Slide Time: 15:46)



The slide is titled "Emerging Infectious Diseases" in blue text. It contains a bulleted list of factors. The first bullet point is "Occurrence of new diseases and increasing incidence of old ones (EID)". The second bullet point is "Factors:", followed by four sub-bullets labeled (a) through (d). At the bottom left is the NPTEL logo, at the bottom center is the email "Email : jashastri@gmail.com", and at the bottom right is the number "29".

- Occurrence of new diseases and increasing incidence of old ones (EID)
- Factors:
 - (a) Evolutionary changes in existing organisms
 - (b) Spread of known diseases into new geographic areas by modern transportation
 - (c) Ecological changes resulting in introduction of unusual agents
 - (d) Emergence of antimicrobial resistance

So what are infectious diseases which are emerging. These are evolutionary changes in the existing organisms, spread of known disease into new geographic areas, ecological changes resulting in introduction of unusual agents and drug resistance.

(Refer Slide Time: 16:06)

Emerging Infectious diseases

The World Health Organization warned in its 2007 report that infectious diseases are emerging at a rate that has not been seen before. Since the 1970s, about 40 infectious diseases have been discovered, including [SARS](#), [MERS](#), [Ebola](#), [chikungunya](#), [avian flu](#), [swine flu](#) and, most recently, [Zika](#).



Emerging Infectious diseases, Baylor College Of Medicine

Email : jsshastr@gmail.com

The World Health Organization has warned in its 2007 report that infectious diseases are emerging at a rate that has not been seen before. Since 1970s, there have been 40 infectious diseases which have been discovered and these are some of them. Just a little bit of information about SARS. So SARS is a respiratory syndrome, the subacute and respiratory syndrome which was, it cropped up in the Guangdong province of China and how near we are to China.

But it never came to India. It knocked the doors very loudly on our territories but somehow we never got infected. We do not know the reason. We presume that we have been infected with so many respiratory viruses which have caused cross immunity. So these are certain suppositions. Ebola virus, now we know that Sierra Leone and other places were in the grip of the Ebola virus infection.

However, fortunately for the Indians, it never peeped into India. Otherwise, I do not know how much, how many communities would have been wiped off because it was a highly transmissible virus, very easy transferred from one individual to another.

(Refer Slide Time: 17:26)

- EID origins are significantly correlated with socio-economic, environmental and ecological factors, and provide a basis for identifying regions where new EIDs are most likely to originate (emerging disease 'hotspots').



Global trends in emerging infectious diseases. NATURE , 451 (7181)
990-U4. 10.1038/nature06536.

The chikungunya, we are in the grip of it, even in Delhi, in Mumbai. Swine flu we had 2 major epidemics in 2009, 2010 as well as in 2015. Avian flu now has been declared in some parts of Maharashtra. So these are certain emerging infectious diseases. So these are significantly correlated with socioeconomic, environmental and ecological factors.

(Refer Slide Time: 17:53)

Will artificial intelligence help to crack biology?

Silicon Valley has the squidgy worlds of biology and disease in its sights



Alphabet
(Google's
parent company),
IBM and Microsoft,
the new Big Idea in
Silicon Valley

32

So this is the last part of my presentation, is something which I thought was important to you people and for us. And that is where we can bridge the gap of artificial intelligence, would it help to crack biology and as I understand, there are lots of companies who are working on this project, the alphabet, IBM, Microsoft, all the big companies in the Silicon Valley.

(Refer Slide Time: 18:22)

AI : Biology & Disease

Chris Bishop of Microsoft Research, in Cambridge, England, observes, one way of thinking about living organisms is to recognise that they are, in essence, complex systems which process information using a combination of hardware and software.

In the squidgy worlds of biology and disease there are problems its software engineers can solve



Email : jshastri@gmail.com

33

So Chris Bishop of Microsoft Research in Cambridge observed one way of thinking about living organisms is to recognise that they are in essence complex systems which process information using a combination of hardware and software. So in the squidgy worlds of biology and disease, there are problems its software engineers can solve. And the solution lies with all of you. So what are the challenges?

Today, I do not know which is the infection which is going to tap my door in winter, my territory. Do I have any information about the Hot Spots in my own country of certain infectious diseases?

(Refer Slide Time: 19:04)

Challenges & Opportunities

- West : GIS mapping for “**Hot Spots**”
- Can Technology be used for
- Forecasting the Spread of Infectious diseases across & within countries ?
- **Will artificial intelligence help to crack biology?**

[Diagnosing illness by smell](#)




Email : jshastri@gmail.com

34

Well in the west, they are using GIS mapping for Hot Spots. So can we use artificial intelligence


for forecasting infectious diseases and I also read that diagnosing illness by smell is also going to be a very near possibility and I am sure it is a Harvard Medical School, MIT engineers and the Baylor School of Medicine and Rice University, all of them, you know, they have these collaborated projects for all these pollutions and I think that is the way forward.

(Refer Slide Time: 19:36)




Drug Money

- The discovery of new drugs is an early test of the belief that AI has much to offer biology and medicine.
- The conventional approach is to screen large numbers of molecules for signs of pertinent biological effect, and then winnow away the dross in a series of more and more expensive tests and trials, in the hope of coming up with a golden nugget at the end.
- This way of doing things is, however, declining in productivity and rising in cost.
- BenevolentAI is a small actor in the theatre of biology and artificial intelligence.
- Two Neuroscience drugs are in the pipeline

 Email : jshastri@gmail.com 35

Currently, we have no preparedness. We really keep banking on good luck and host immunity for not getting these infectious diseases. Well I have also read about drug discovery, new molecules are discovered through artificial intelligence and this is one actor in that theatre of biology and artificial intelligence and 2 neuroscience drugs in the pipeline had the molecules have been discovered by artificial intelligence.

(Refer Slide Time: 20:05)



Now these are, this was an article in JAMA where you can detect diabetic retinopathy and macular oedema, 2 causes of blindness. Through artificial intelligence, there are lots of companies which are, you know, coming up with artificial intelligence group acts to diagnose the patient's queries about symptoms and diagnose the conditions. IBM is able to suggest treatment plans for a number of different cancers and all this has a potential to transform doctors' abilities to screen for and diagnose disease.

Where is it important? It is extremely important where the doctor-patient ratio is skewed. If you go to London, the NHS will give you an appointment after 2 months if you go with a lump in breast and go for an appointment after 2 months, I think you will die of anxiety. So in such conditions, these apps are of very great use where they give you some direction about what probably the condition could be and where the waiting period, see India is the best place for healthcare.

I can just pay walk into any doctors' clinic and get myself examined. It is not the same. In the United States, you are completely bound by your insurance policy as to where you go. If your insurance policy expects you to go to one particular doctor, switching doctors is really going to make holes in your pocket. So these apps are going to be of great use in such places to give some tentative diagnosis.

(Refer Slide Time: 21:42)

Words of Caution

- Most known protein structures have been worked out from crystallised versions of the molecule, held tight by networks of chemical bonds.
- In reality, proteins are flexible, but that is much harder to deal with.
- Quoting sir issac Newton "If I have seen further, it is by standing on the shoulders of giants." If the brains of those giants happen to be made of silicon chips, so be it.



But of course, it comes with a word of caution. Most known protein structures have been worked out from crystallised versions whereas in reality proteins are flexible. More work needs to be done at the molecular level and quoting Sir Issac Newton, "If I have seen further, it is by standing on the shoulders of giants. And if the brains of those giants happen to be made of silicon chips, so be it."

(Refer Slide Time: 22:07)



So to end my talk, I would say please stay focus, work consistently on a problem, maintain quality at all costs and come up with a low cost technology. Ours is a developing country, we cannot use very expensive diagnostics for patient care. If solutions have to be afford at bedside, they have to be affordable.

(Refer Slide Time: 22:35)

THANK YOU FOR YOUR ATTENTION

when you feel like giving up,
look back at how far you've come.



be strong. stay on your path.
never stop going.




Email : jshastri@gmail.com

41


So thank you all for your attention and when you feel like giving up, look back at how far you have come. Be strong, stay on your path and never stop going. Thank you very much.

(Refer Slide Time: 22:49)

Finding affordable bedside diagnostics



THE FUTURE



42

(Refer Slide Time: 22:51)

TAKE HOME MESSAGE

- One of the biggest challenge a clinician faces is to identify the causative agent of an infectious disease
- Is it a bacteria, a virus, fungus or a parasite?
- The existing methods that can be employed to answer these questions are very time consuming
- The clinician has to wait a couple of days to get the answer



(Refer Slide Time: 23:00)

TAKE HOME MESSAGE

- So the need of the hour is a point of care test (POC)
- Very sensitive and specific test which is available at the bedside
- A lab on chip to know whether the infectious agent is a bacteria, virus, fungus or parasite within a few minutes
- This kind of early diagnosis allows doctors to treat the patient with the correct drug for the disease

(Refer Slide Time: 23:10)

TAKE HOME MESSAGE

- Reduces drug resistance and turn-around time for diagnosis of infectious diseases
- Provides accurate diagnosis

(Refer Slide Time: 23:12)

AI & Clinical Care

- Artificial intelligence will also move into clinical care.
- Antonio Crimini, who, works at Microsoft Research in Cambridge, observes that today the process of delineating the edges of tumours in images generated by MRI machines and CT scans is done by hand.
- This is tedious and long-winded (it can take up to four hours).
- AI can reduce the time taken to minutes, or even seconds—and the results are completely consistent, unlike those arrived at by human doctors.



(Refer Slide Time: 23:19)

AI & Clinical Care

- The discovery of new drugs is an early test of the belief that AI has much to offer in biology and medicine.
- AI will be able to crack open the inner workings of a cell.